Real‐world non‐interventional long‐term post‐authorisation safety study of ruxolitinib in myelofibrosisFiorenza Barraco, Heinz Gisslinger, Richard Greil et al.|British Journal of Haematology|2020Cited by 30
P554: RESULTS OF A RANDOMIZED PLACEBO-CONTROLLED PHASE 2 STUDY OF HYPOMETHYLATING AGENTS WITH OR WITHOUT ELTROMBOPAG IN ELDERLY AML PATIENTS (DELTA)Katja Sockel, Uwe Platzbecker, Martin Kaufmann et al.|HemaSphere|2023Cited by 0
Hypomethylating Therapy With or Without Eltrombopag in Elderly Patients With Acute Myeloid Leukemia: Results From the Randomized, Placebo‐Controlled Phase 2 <scp>DELTA</scp> TrialKatja Sockel, Uwe Platzbecker, Christoph Röllig et al.|American Journal of Hematology|2025Cited by 0